Systemic enhancement of antitumour immunity by peritumourally implanted immunomodulatory macroporous scaffolds.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 36550304.
- Also identified by DOI 10.1038/s41551-022-00977-0 and PMC identifier 9940651.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A tumour microenvironment abundant in regulatory T (T<sub>reg</sub>) cells aids solid tumours to evade clearance by effector T cells. Systemic strategies to suppress T<sub>reg</sub> cells or to augment immunity can elicit autoimmune side effects, cytokine storms and other toxicities. Here we report the design, fabrication and therapeutic performance of a biodegradable macroporous scaffold, implanted peritumourally, that releases a small-molecule inhibitor of transforming growth factor β to suppress T<sub>reg</sub> cells, chemokines to attract effector T cells and antibodies to stimulate them. In two mouse models of aggressive tumours, the implant boosted the recruitment and activation of effector T cells into the tumour and depleted it of T<sub>reg</sub> cells, which resulted in an 'immunological abscopal effect' on distant metastases and in the establishment of long-term memory that impeded tumour recurrence. We also show that the scaffold can be used to deliver tumour-antigen-specific T cells into the tumour. Peritumourally implanted immunomodulatory scaffolds may represent a general strategy to enhance T-cell immunity and avoid the toxicities of systemic therapies.
Medical subject headings
- T-Lymphocytes, Regulatory
- Neoplasms